E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Uncontrolled asthma despite the use of an inhaled corticosteroid
and a second controller medication. |
|
E.1.1.1 | Medical condition in easily understood language |
Uncontrolled asthma despite daily therapy. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Respiratory Tract Diseases [C08] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10003553 |
E.1.2 | Term | Asthma |
E.1.2 | System Organ Class | 10038738 - Respiratory, thoracic and mediastinal disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
• The efficacy of lebrikizumab compared with placebo as measured by the rate of exacerbations
• The safety of lebrikizumab compared with placebo
• Periostin as a predictive biomarker (diagnostic)
• The efficacy and safety of different dose levels of lebrikizumab compared to placebo. |
|
E.2.2 | Secondary objectives of the trial |
The efficacy of lebrikizumab compared with placebo with respect to lung function, time to first exacerbation, fractional exhaled nitric oxide (FeNO), asthma-specific health-related quality of life, rescue medication use (i.e. short-acting β-agonists [SABA]), and health care utilization. |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
ECG SUBSTUDY version 2 dated 5 April 2012 - IN ASSOCIATION WITH LEBRIKIZUMAB STUDY GB27862: A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN PATIENTS WITH UNCONTROLLED ASTHMA WHO ARE ON INHALED CORTICOSTEROIDS AND A SECOND CONTROLLER MEDICATION.
The primary objective of this substudy is as follows:
• To evaluate the effect of lebrikizumab treatment on cardiac repolarization on the basis of prolongation of the QT interval in surface ECGs in patients with uncontrolled asthma.
The secondary objectives of this substudy are as follows:
• To evaluate the effect of lebrikizumab treatment on other ECG measures
• To assess the effect of lebrikizumab treatment on ECG morphology. |
|
E.3 | Principal inclusion criteria |
- Ability and willingness to provide written informed consent and to comply with the study protocol
- 18–75 years old at screening
- Asthma diagnosis for ≥ 12 months prior to the start of screening
- Bronchodilator response (defined as a minimum 12% relative improvement in the volume of FEV1 after bronchodilator administration) during the screening period
- Pre-bronchodilator FEV1 40%–80% of predicted
- On ICS (500-2000 µg/day of fluticasone propionate DPI or equivalent, total daily dose) for ≥ 6 months prior to the start of screening
- On an eligible second controller medication for 6 months prior to the start of screening
- Uncontrolled asthma demonstrated during the screening period
- Chest X-ray or computed tomography (CT) scan obtained within 12 months prior to screening or chest X-ray during the screening period confirming the absence of other lung disease
- Demonstrated adherence with controller medication during the screening period.
|
|
E.4 | Principal exclusion criteria |
- History of a severe allergic reaction or anaphylactic reaction to a biologic agent
- Daily or alternate day oral corticosteroid maintenance therapy within the 3 months prior to screening
- Treatment with systemic corticosteroids within the 4 weeks prior to, or at anytime during the screening period
- Recent major episode of infection
- Active parasitic infection or Listeria monocytogenes infection within the 6 months prior to screening
- Active tuberculosis requiring treatment within the 12 months prior to screening
- Known immunodeficiency, including, but not limited to, HIV infection
- Evidence of acute or chronic hepatitis or known liver cirrhosis
- History of cystic fibrosis, chronic obstructive pulmonary disease, and/or other clinically significant lung disease other than asthma
- Known current malignancy or current evaluation for a potential malignancy
- Other clinically significant medical disease that is uncontrolled despite treatment or that is likely, in the opinion of the investigator, to require a change in therapy or impact the ability to participate in the study
- History of alcohol, drug, or chemical abuse
- Current smoker (cigarettes, pipe, cigar, or marijuana) or former smoker with a smoking history of > 10 pack-years
- Current use of an immunomodulatory/immunosuppressive therapy or past use within 3 months or 5 drug half-lives (whichever is longer) prior to screening
- Use of a biologic therapy including omalizumab (Xolair) at any time during the 6 months prior to screening
- Use of zileuton (ZYFLO) or roflumilast (Daxas, Daliresp) at any time during the 6 months prior to screening
- Treatment with an investigational agent within 30 days of screening (or 5 half lives of the investigational agent, whichever is longer)
- Receipt of a live/attenuated vaccine within the 4 weeks prior to sreening
- Female patients who are pregnant or lactating or unwilling to use a highly effective method of contraception
- Body mass index > 38 kg/m2
- Body weight < 40 kg. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Rate of asthma exacerbations. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
• Frequency of adverse events during the 52-week placebo-controlled period
• Severity of adverse events during the 52-week placebo-controlled period
• Incidence of anti-therapeutic antibodies during the study relative to the incidence at baseline
• Frequency and severity of adverse events during the 52-week active-treatment extension and during the 24-week safety follow-up period. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 4 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 62 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Argentina |
Australia |
Brazil |
Bulgaria |
Canada |
Chile |
China |
Colombia |
Czech Republic |
France |
Germany |
Hungary |
India |
Israel |
Italy |
Japan |
Korea, Republic of |
Mexico |
Peru |
Poland |
Russian Federation |
Slovakia |
South Africa |
Spain |
Turkey |
Ukraine |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of the study is defined as the date when the last patient, last visit (LPLV) occurs. The LPLV is expected to occur a maximum of 124 weeks after the last patient is enrolled and
randomized into the study. This timeframe includes the 52-week placebo-controlled period and a maximum of an additional 52-week active-treatment extension followed by the safety follow-up
period. All patients will be followed for safety for 24 weeks after the last dose of study treatment. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 4 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |